Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2021-08-29 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
长城证券股份有限公司关于深圳市浙江泰林生物技术股份有限公司2021年半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021年半年度跟踪报告' which translates to '2021 Half-Year Tracking Report' for Zhejiang Tailin Biotechnology Co., Ltd. It is issued by the sponsoring institution Great Wall Securities Co., Ltd. The content includes detailed oversight and supervision activities related to the company's internal controls, information disclosure, fundraising supervision, governance, and compliance during the half-year period. It also discusses the sponsor's work, findings, and measures taken, as well as company and shareholder commitment fulfillment. The document length is 2205 characters, which is relatively short but contains substantive content and analysis related to the half-year period. It is not merely an announcement or a certification but a report with detailed supervisory and operational information for the half-year period. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-29 Chinese
关于全资子公司变更经营范围并完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the change in business scope of its wholly-owned subsidiary Zhejiang Tailin Life Sciences Co., Ltd. It details the changes in the subsidiary's business license and registration information. The document is short (1980 characters) and focuses on operational and registration updates rather than financial data or report content. There is no indication of financial statements, audit information, or regulatory certifications. It is not a report itself but an announcement of a corporate change. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-29 Chinese
关于《对浙江泰林生物技术股份有限公司的关注函》的回复公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Zhejiang Tailin Biotechnology Co., Ltd. responding to a regulatory inquiry from the Shenzhen Stock Exchange. It addresses questions about the company's business fundamentals, stock price fluctuations, product lines, shareholder activities, and information disclosure compliance. The content is a detailed reply to a regulatory concern letter (关注函), which is a type of regulatory filing or response to an exchange inquiry. The document does not contain financial statements or quarterly/annual report data but rather explanations and clarifications related to regulatory oversight. The length is under 5,000 characters, and it is not a report itself but a regulatory response. Therefore, it fits best under Regulatory Filings (RNS).
2021-07-22 Chinese
泰林生物股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding abnormal stock price fluctuations over two consecutive trading days, with detailed explanations and risk warnings to investors. It references stock price changes, trading rules from the Shenzhen Stock Exchange, and clarifies that no undisclosed material information exists. The document is relatively short (2179 characters) and serves as a regulatory disclosure about stock price abnormality rather than a financial report or earnings release. It does not contain financial statements, management discussion, or detailed financial data. This type of announcement fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-07-22 Chinese
2021 泰林生物股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by Zhejiang Tailin Biotechnology Co., Ltd. It discusses the stock price movements over specific dates, references prior annual and semi-annual reports, and provides risk warnings to investors. It does not contain actual financial statements or detailed financial data but rather serves as a regulatory disclosure about unusual stock price behavior and related risk factors. The document length is 2498 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-07-20 Chinese
泰林生物：关于取得商标注册证书、专利证书及软件著作权证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the acquisition of trademark registration certificates, patent certificates, and software copyright certificates. It details the number and types of intellectual property rights obtained, their registration numbers, and the benefits to the company. The document is relatively short (2345 characters) and does not contain financial data, management discussion, or regulatory certifications. It is an announcement of intellectual property achievements rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2021-07-16 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.